Advancing Pharmaceutical Innovation Through Global Collaboration | LBE Pharma at CPHI Europe 2026

CPHI Europe 2026 successfully concluded in Milan, Italy, bringing all pharmaceutical industry leaders and professionals around the world to explore new opportunities in innovation, development, and manufacturing.

From October 6–8, LBE Pharma showcased its three proprietary technology platforms at Booth 7D139, with global industry partners in discussions on pharmaceutical product development, manufacturing, and potential collaborations.

From the integrated development of drug formulations and delivery devices to dual-chamber prefilled systems and long-acting sustained-release formulations, our participation focused on a central objective: translating platform technologies into practical development and commercialization solutions for our partners.

Meaningful Connections: Aligning Technology with Project Needs

Throughout the three-day exhibition, our team engaged in productive face-to-face discussions with industry professionals, exchanging insights on formulation characteristics, drug delivery approaches, process scale-up, and target-market requirements.

These interactions provided valuable perspectives for subsequent technical evaluations and potential collaborations.

Three Proprietary Technology Platforms: Bridging Development and Manufacturing

1. Drug–Device Combination Product Development and Manufacturing Platform

Our platform focuses on the integrated development of drug formulations and delivery devices, connecting formulation and process development, device compatibility, user requirements, and manufacturing and assembly processes.

With applications including autoinjector-based delivery systems, the platform supports the early identification of critical interfaces between product design and manufacturability, helping partners address key development considerations from the outset.

2. Dual-Chamber Prefilled Drug Product Development and Manufacturing Platform

Designed for injectable formulations requiring separate storage and mixing or reconstitution prior to administration, this platform integrates formulation development, dual-chamber container compatibility, filling operations, and lyophilization processes.

By incorporating storage stability, container closure integrity (CCI), and mixing or reconstitution performance into development evaluations, the platform supports a structured transition from formulation design to manufacturing process development.

3. Long-Acting Sustained-Release Formulation Development and Manufacturing Platform

Our platform encompasses multiple formulation technologies, including microcrystals, microspheres, and in situ forming gels, with a focus on drug release profiles, formulation stability, and process scale-up.

Technology selection is guided by product-specific objectives, while analytical characterization and manufacturing requirements are integrated throughout development to support the continued advancement of long-acting formulation projects.

4.Lifecycle Management: Supporting Projects from Development to Commercialization

Building on experience gained through our proprietary development programs, LBE Pharma applies its platform capabilities across different stages of customer projects.

During early development, we focus on defining target product profiles and evaluating technical feasibility. Throughout formulation and process development, we work to align formulation design, manufacturing processes, and analytical methodologies.

As projects progress toward technology transfer and scale-up, our priorities include process reproducibility, quality control, and manufacturing compatibility.

To support subsequent regulatory and supply requirements, we also address documentation preparation, process optimization, and change assessments in accordance with project milestones and target-market expectations.

Through a product lifecycle-oriented approach, LBE Pharma aims to facilitate continuity across pharmaceutical R&D, technology transfer, and commercial manufacturing readiness.

We remain committed to strengthening our technology capabilities in drug delivery, controlled release, formulation stability, and pharmaceutical process development, providing diversified formulation development solutions for a broad range of drug products.

See You in Shanghai — Let's Continue the Conversation!

A sincere thank you to all our industry partners and visitors who stopped by Booth 7D139 during CPHI Europe 2026.

We look forward to reconnecting at CPHI Shanghai 2027, where we will continue exploring development and manufacturing opportunities in drug–device combination products, dual-chamber prefilled systems, and long-acting sustained-release formulations.

CPHI Shanghai 2027 | Booth 52J78

We welcome you to connect with our team in advance to discuss your project requirements and arrange a meeting.

Together, let's advance pharmaceutical innovation through technology and collaboration.

#LBE Pharma #CPHI Europe 2026 #CPHI Shanghai 2027 #Pharmaceutical Development #Drug Delivery #Drug Device Combination Products #Prefilled Syringes #Long Acting Injectables #Controlled Release #Pharmaceutical Manufacturing